0000928816-17-000036.txt : 20170119 0000928816-17-000036.hdr.sgml : 20170119 20170119091510 ACCESSION NUMBER: 0000928816-17-000036 CONFORMED SUBMISSION TYPE: 485BPOS PUBLIC DOCUMENT COUNT: 13 FILED AS OF DATE: 20170119 DATE AS OF CHANGE: 20170119 EFFECTIVENESS DATE: 20170119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PUTNAM GLOBAL HEALTH CARE FUND CENTRAL INDEX KEY: 0000357295 IRS NUMBER: 046471950 STATE OF INCORPORATION: MA FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 485BPOS SEC ACT: 1933 Act SEC FILE NUMBER: 002-75863 FILM NUMBER: 17534932 BUSINESS ADDRESS: STREET 1: ONE POST OFFICE SQ STREET 2: MAILSTOP A 14 CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 8002251581 MAIL ADDRESS: STREET 1: ONE POST OFFICE SQ STREET 2: MAILSTOP A 14 CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: PUTNAM HEALTH SCIENCES TRUST DATE OF NAME CHANGE: 19920703 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PUTNAM GLOBAL HEALTH CARE FUND CENTRAL INDEX KEY: 0000357295 IRS NUMBER: 046471950 STATE OF INCORPORATION: MA FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 485BPOS SEC ACT: 1940 Act SEC FILE NUMBER: 811-03386 FILM NUMBER: 17534933 BUSINESS ADDRESS: STREET 1: ONE POST OFFICE SQ STREET 2: MAILSTOP A 14 CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 8002251581 MAIL ADDRESS: STREET 1: ONE POST OFFICE SQ STREET 2: MAILSTOP A 14 CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: PUTNAM HEALTH SCIENCES TRUST DATE OF NAME CHANGE: 19920703 0000357295 S000005666 PUTNAM GLOBAL HEALTH CARE FUND C000015515 Class A Shares PHSTX C000015516 Class B Shares PHSBX C000015517 Class C Shares PCHSX C000015518 Class M Shares PHLMX C000015519 Class R Shares PHSRX C000015520 Class Y Shares PHSYX 485BPOS 1 a_ghccvr.htm PUTNAM GLOBAL HEALTH CARE FUND a_ghccvr.htm
As filed with the Securities and Exchange Commission on  
January 19, 2017  
 
Registration No. 811-03386 
2-75863 
----------------------------------------------------------------   
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
----------------  
FORM N-1A  
  ---- 
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933   
/ X /
  ---- 
  ---- 
Pre-Effective Amendment No.  /    / 
  ---- 
  ---- 
Post-Effective Amendment No. 43  / X / 
and  ---- 
  ---- 
REGISTRATION STATEMENT UNDER THE INVESTMENT COMPANY  / X / 
ACT OF 1940  ---- 
---- 
Amendment No. 44  / X / 
(Check appropriate box or boxes)  ---- 
 
---------------  
PUTNAM GLOBAL HEALTH CARE FUND  
(Exact name of registrant as specified in charter)  
 
One Post Office Square, Boston, Massachusetts 02109  
(Address of principal executive offices)  
 
Registrant's Telephone Number, including Area Code  
(617) 292-1000  
----------------  

 



  It is proposed that this filing will become effective 
  (check appropriate box) 
----   
/    /  immediately upon filing pursuant to paragraph (b) 
----   
----   
/ X /  on December 30, 2016 pursuant to paragraph (b) 
----   
----   
/    /  60 days after filing pursuant to paragraph (a) (1) 
----   
----   
/    /  on (date) pursuant to paragraph (a) (1) 
----   
----   
/    /  75 days after filing pursuant to paragraph (a) (2) 
----   
----   
/    /  on (date) pursuant to paragraph (a) (2) of Rule 485. 
----   
 
If appropriate, check the following box: 
----   
/    /  this post-effective amendment designates a new 
----  effective date for a previously filed post-effective amendment. 
 
  -------------- 
 
  ROBERT T. BURNS, Vice President 
  PUTNAM GLOBAL HEALTH CARE FUND 
  One Post Office Square 
  Boston, Massachusetts 02109 
  (Name and address of agent for service) 
  --------------- 
  Copy to: 
  BRYAN CHEGWIDDEN, Esquire 
  ROPES & GRAY LLP 
  1211 Avenue of the Americas 
  New York, New York 10036 

 


 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, and the Investment Company Act of 1940, as amended, the Registrant certifies that it meets all of the requirements for effectiveness of this Registration Statement under Rule 485(b) under the Securities Act of 1933, as amended, and has duly caused this Amendment to its Registration Statement to be signed on its behalf by the undersigned, duly authorized, in the City of Boston, and The Commonwealth of Massachusetts, on the 19th day of January, 2017.

 

 

PUTNAM GLOBAL HEALTH CARE FUND

 

By: /s/ Jonathan S. Horwitz, Executive Vice President, Principal Executive Officer and Compliance Liaison

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment to the Registration Statement has been signed below by the following persons in the capacities and on the date indicated:

 

Signature Title

 

Jameson A. Baxter* Chair, Board of Trustees

 

Kenneth R. Leibler* Vice Chair, Board of Trustees

 

Robert L. Reynolds* President and Trustee

 

Jonathan S. Horwitz* Executive Vice President, Principal Executive
  Officer and Compliance Liaison

 

Janet C. Smith** Vice President, Principal Financial Officer, Principal
  Accounting Officer and Assistant Treasurer

 

Liaquat Ahamed* Trustee

 

Ravi Akhoury* Trustee

 

Barbara M. Baumann* Trustee

 

Robert J. Darretta* Trustee

 

Katinka Domotorffy* Trustee

 

John A. Hill* Trustee

 

Paul L. Joskow* Trustee

 

Robert E. Patterson* Trustee

 

George Putnam, III* Trustee

 

W. Thomas Stephens * Trustee

 

 

 

By:/s/ Jonathan S. Horwitz, as Attorney-in-Fact

January 19, 2017

 

*Signed pursuant to power of attorney filed in Post-Effective Amendment No.34 to the Registrant’s Registration Statement on December 28, 2012.

 

**Signed pursuant to power of attorney filed in Post-Effective Amendment No.42 to the Registrant’s Registration Statement on December 27, 2016.

 

 

 

 

EX-101.INS 2 phstx-20151223.xml XBRL INSTANCE FILE 0000357295 2015-12-31 2016-12-30 0000357295 PHSTX:S000005666Member 2015-12-31 2016-12-30 0000357295 PHSTX:S000005666Member PHSTX:C000015515Member 2015-12-31 2016-12-30 0000357295 PHSTX:S000005666Member PHSTX:C000015516Member 2015-12-31 2016-12-30 0000357295 PHSTX:S000005666Member PHSTX:C000015517Member 2015-12-31 2016-12-30 0000357295 PHSTX:S000005666Member PHSTX:C000015518Member 2015-12-31 2016-12-30 0000357295 PHSTX:S000005666Member PHSTX:C000015519Member 2015-12-31 2016-12-30 0000357295 PHSTX:S000005666Member PHSTX:C000015520Member 2015-12-31 2016-12-30 0000357295 PHSTX:S000005666Member PHSTX:C000015515Member rr:AfterTaxesOnDistributionsMember 2015-12-31 2016-12-30 0000357295 PHSTX:S000005666Member PHSTX:C000015515Member rr:AfterTaxesOnDistributionsAndSalesMember 2015-12-31 2016-12-30 0000357295 PHSTX:S000005666Member PHSTX:MSCIWorldHealthCareIndexMember 2015-12-31 2016-12-30 iso4217:USD xbrli:pure 485BPOS 2015-12-31 PUTNAM GLOBAL HEALTH CARE FUND 0000357295 false PHSTX 2016-12-30 2016-12-30 2016-12-30 <b>Fund summary</b> <b>Goal</b> Putnam Global Health Care Fund seeks capital appreciation. <b>Fees and expenses</b> The following table describes the fees and expenses you may pay if you buy and hold shares of the fund. You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $50,000 in Putnam funds. More information about these and other discounts is available from your financial advisor and in<i> How do I buy fund shares?</i> beginning on page 53 of the fund&#8217;s prospectus and in <i>How to buy shares</i> beginning on page II-1 of the fund&#8217;s statement of additional information (SAI). <b>Shareholder fees </b><i>(fees paid directly from your investment) <b>Annual fund operating expenses </b><i>(expenses you pay each year as a percentage of the value of your investment)</i> 0.0575 0 0 0.0350 0 0 0.0100 0.0500 0.0100 0 0 0 <div style="display: none">~ http://xbrl.sec.gov/rr/role/ShareholderFeesData column period compact * column dei_LegalEntityAxis compact PHSTX_S000005666Member column rr_ProspectusShareClassAxis compact * row primary compact * ~</div> <b>Example</b> <b>Portfolio turnover</b> The fund pays transaction-related costs, such as commissions, when it buys and sells securities (or &#147;turns over&#148; its portfolio). A higher turnover rate may indicate higher transaction costs and may result in higher taxes when the fund&#146;s shares are held in a taxable account. These costs, which are not reflected in annual fund operating expenses or the above example, affect fund performance. The fund&#146;s turnover rate in the most recent fiscal year was 16%. 0.16 You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $50,000 in Putnam funds. More information about these and other discounts is available from your financial advisor and in<i> How do I buy fund shares?</i> beginning on page 53 of the fund&#8217;s prospectus and in <i>How to buy shares</i> beginning on page II-1 of the fund&#8217;s statement of additional information (SAI). 50000 The following hypothetical example is intended to help you compare the cost of investing in the fund with the cost of investing in other funds. It assumes that you invest $10,000 in the fund for the time periods indicated and then, except as indicated, redeem all your shares at the end of those periods. It assumes a 5% return on your investment each year and that the fund&#8217;s operating expenses remain the same. Your actual costs may be higher or lower. <b>Investments</b> For this non-diversified fund concentrating in the health care industries, we invest mainly in common stocks (growth or value stocks or both) of large and midsize companies worldwide that we believe have favorable investment potential. Under normal circumstances, we invest at least 80% of the fund&#8217;s net assets in securities of companies in the health care industries. This policy may be changed only after 60 days&#8217; notice to shareholders. Potential investments include companies that manufacture health care supplies or provide health care-related services, and companies in the research, development, production and marketing of pharmaceuticals and biotechnology products. We may purchase stocks of companies with stock prices that reflect a value lower than that which we place on the company. We may also consider other factors that we believe will cause the stock price to rise. We may consider, among other factors, a company&#8217;s valuation, financial strength, growth potential, competitive position in its industry, projected future earnings, cash flows and dividends when deciding whether to buy or sell investments. We may also use derivatives, such as futures, options, certain foreign currency transactions, warrants and swap contracts, for both hedging and non-hedging purposes, and may engage in short sales of securities. <b>Risks</b> It is important to understand that you can lose money by investing in the fund.<br /> <br /> The value of stocks in the fund&#8217;s portfolio may fall or fail to rise over extended periods of time for a variety of reasons, including general financial market conditions, changing market perceptions, changes in government intervention in financial markets, and factors related to a specific issuer or industry. These and other factors may also lead to increased volatility and reduced liquidity in the fund&#8217;s portfolio holdings. Growth stocks may be more susceptible to earnings disappointments, and value stocks may fail to rebound. These risks are generally greater for small and midsize companies. The health care industries may be affected by technological obsolescence, changes in regulatory approval policies for drugs, medical devices or procedures and changes in governmental and private payment systems. Our policy of concentrating on a limited group of industries and the fund&#8217;s &#8220;non-diversified&#8221; status, which means the fund may invest a greater percentage of its assets in fewer issuers than a &#8220;diversified fund,&#8221; can increase the fund&#8217;s vulnerability to adverse developments affecting a single industry or issuer, which may result in greater losses and volatility for the fund. The value of international investments traded in foreign currencies may be adversely impacted by fluctuations in exchange rates. International investments, particularly investments in emerging markets, may carry risks associated with potentially less stable economies or governments (such as the risk of seizure by a foreign government, the imposition of currency or other restrictions, or high levels of inflation or deflation), and may be or become illiquid. Our use of derivatives may increase the risks of investing in the fund by increasing investment exposure (which may be considered leverage) or, in the case of many over-the-counter instruments, because of the potential inability to terminate or sell derivatives positions and the potential failure of the other party to the instrument to meet its obligations. Our use of short selling may result in losses if the securities appreciate in value.<br /> <br /> The fund may not achieve its goal, and it is not intended to be a complete investment program. An investment in the fund is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.<br /> It is important to understand that you can lose money by investing in the fund. An investment in the fund is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency. <b>Performance</b> The performance information below gives some indication of the risks associated with an investment in the fund by showing the fund&#146;s performance year to year and over time. The bar chart does not reflect the impact of sales charges. If it did, performance would be lower. Please remember that past performance is not necessarily an indication of future results. Monthly performance figures for the fund are available at putnam.com. The performance information below gives some indication of the risks associated with an investment in the fund by showing the fund&#146;s performance year to year and over time. putnam.com Please remember that past performance is not necessarily an indication of future results. <b>Annual total returns for class A shares before sales charges</b> The bar chart does not reflect the impact of sales charges. If it did, performance would be lower. Year-to-date performance<br /><b>through 9/30/16&#160;&#160;&#160;&#160;-6.28%<br /><br /></b>Best calendar quarter<br /><b>Q1 2013&#160;&#160;&#160;13.14%<br /><br /></b>Worst calendar quarter<br /><b>Q3 2011 &#160;&#160;&#160;&#160;-17.98%</b> Year-to-date performance through 2016-09-30 -0.0628 Best calendar quarter 2013-03-31 0.1314 Worst calendar quarter 2011-09-30 -0.1798 After-tax returns reflect the historical highest individual federal marginal income tax rates and do not reflect state and local taxes. Actual after-tax returns depend on an investor&#8217;s tax situation and may differ from those shown. After-tax returns are shown for class A shares only and will vary for other classes. After-tax returns reflect the historical highest individual federal marginal income tax rates and do not reflect state and local taxes.<br /> Actual after-tax returns depend on an investor&#8217;s tax situation and may differ from those shown. After-tax returns are shown for class A shares only and will vary for other classes. These after-tax returns do not apply if you hold your fund shares through a 401(k) plan, an IRA, or another tax-advantaged arrangement.<br /> <br /> Class B share performance reflects conversion to class A shares after eight years.<br /> <b>Average annual total returns after sales charges </b><i>(for periods ending 12/31/15)</i> For this non-diversified fund concentrating in the health care industries, we invest mainly in common stocks (growth or value stocks or both) of large and midsize companies worldwide that we believe have favorable investment potential. Our policy of concentrating on a limited group of industries and the fund's "non-diversified" status, which means the fund may invest a greater percentage of its assets in fewer issuers than a "diversified fund," can increase the fund's vulnerability to adverse developments affecting a single industry or issuer, which may result in greater losses and volatility for the fund. 0.0062 0.0062 0.0062 0.0062 0.0062 0.0062 0.0025 0.0100 0.0100 0.0075 0.0050 0.0000 0.0022 0.0022 0.0022 0.0022 0.0022 0.0022 0.0109 0.0184 0.0184 0.0159 0.0134 0.0084 1827 1962 2159 2173 1613 1037 1141 1195 995 1185 734 466 902 879 579 834 425 268 680 687 287 506 136 86 1962 2159 995 995 579 579 187 187 <div style="display: none">~ http://xbrl.sec.gov/rr/role/OperatingExpensesData column period compact * column dei_LegalEntityAxis compact PHSTX_S000005666Member column rr_ProspectusShareClassAxis compact * row primary compact * ~</div> <div style="display: none">~ http://xbrl.sec.gov/rr/role/ExpenseExample column period compact * column dei_LegalEntityAxis compact PHSTX_S000005666Member column rr_ProspectusShareClassAxis compact * row primary compact * ~</div> <div style="display: none">~ http://xbrl.sec.gov/rr/role/ExpenseExampleNoRedemption column period compact * column dei_LegalEntityAxis compact PHSTX_S000005666Member column rr_ProspectusShareClassAxis compact * row primary compact * ~</div> 0.0298 -0.0063 -0.1712 0.2517 0.0206 -0.0141 0.2198 0.4172 0.2747 0.0754 <div style="display: none">~ http://xbrl.sec.gov/rr/role/BarChartData column period compact * column dei_LegalEntityAxis compact PHSTX_S000005666Member column rr_ProspectusShareClassAxis compact * row primary compact * ~</div> 0.0909 0.0908 0.0891 0.0880 0.0946 0.1001 0.0723 0.0704 0.0925 0.1710 0.1740 0.1761 0.1707 0.1820 0.1879 0.1451 0.1335 0.1715 0.0135 0.0223 0.0582 0.0325 0.0728 0.0781 -0.0151 0.0298 0.0660 <div style="display: none">~ http://xbrl.sec.gov/rr/role/PerformanceTableData column period compact * column dei_LegalEntityAxis compact PHSTX_S000005666Member column rr_ProspectusShareClassAxis compact * row primary compact * ~</div> Applies only to certain redemptions of shares bought with no initial sales charge. This charge is phased out over six years. This charge is eliminated after one year. Restated to reflect current fees resulting from a change to the fund's investor servicing arrangements effective September 1, 2016. EX-101.SCH 3 phstx-20151223.xsd XBRL SCHEMA FILE EX-101.DEF 4 phstx-20151223_def.xml XBRL DEFINITION FILE EX-101.LAB 5 phstx-20151223_lab.xml XBRL LABEL FILE Putnam Global Health Care Fund Legal Entity [Axis] Class A Share Class [Axis] Class B Class C Class M Class R Class Y after taxes on distributions Performance Measure [Axis] after taxes on distributions and sale of fund shares MSCI World Health Care Index (ND) (no deduction for fees, expenses or taxes, other than withholding taxes on reinvested dividends) Risk/Return [Heading] Objective [Heading] Objective, Primary [Text Block] Objective, Secondary [Text Block] Expense [Heading] Expense Narrative [Text Block] Shareholder Fees Caption [Text] Shareholder Fees [Table] Operating Expenses Caption [Text] Annual Fund Operating Expenses [Table] Expense Footnotes [Text Block] Expenses Deferred Charges [Text Block] Expenses Range of Exchange Fees [Text Block] Expense Example [Heading] Expense Example by Year [Heading] Expense Example Narrative [Text Block] Expense Example by, Year, Caption [Text] Expense Example, With Redemption [Table] Expense Example, No Redemption Narrative [Text Block] Expense Example, No Redemption, By Year, Caption [Text] Expense Example, No Redemption [Table] Expense Example Footnotes [Text Block] Expense Example Closing [Text Block] Portfolio Turnover [Heading] Portfolio Turnover [Text Block] Strategy [Heading] Strategy Narrative [Text Block] Risk [Heading] Risk Narrative [Text Block] Risk Footnotes [Text Block] Risk Closing [Text Block] Bar Chart and Performance Table [Heading] Performance Narrative [Text Block] Bar Chart Narrative [Text Block] Bar Chart [Heading] Bar Chart [Table] Bar Chart Footnotes [Text Block] Bar Chart Closing [Text Block] Performance Table Heading Performance Table Narrative Performance [Table] Market Index Performance [Table] Performance Table Footnotes Performance Table Closing [Text Block] Shareholder Fees Column [Text] Maximum Cumulative Sales Charge (as a percentage of Offering Price) Maximum Cumulative Sales Charge (as a percentage) Maximum sales charge (load) imposed on purchases (as a percentage of offering price) Maximum Deferred Sales Charge (as a percentage of Offering Price) Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) Maximum Sales Charge on Reinvested Dividends and Distributions (as a percentage) Redemption Fee (as a percentage of Amount Redeemed) Redemption Fee Exchange Fee (as a percentage of Amount Redeemed) Exchange Fee Maximum Account Fee (as a percentage of Assets) Maximum Account Fee Shareholder Fee, Other Operating Expenses Column [Text] Management fees Distribution and service (12b-1) fees Distribution or Similar (Non 12b-1) Fees Component1 Other Expenses Component2 Other Expenses Component3 Other Expenses Other expenses Acquired Fund Fees and Expenses Total annual fund operating expenses Fee Waiver or Reimbursement Net Expenses (as a percentage of Assets) Expense Example, By Year, Column [Text] Expense Example, with Redemption, 1 Year Expense Example, with Redemption, 3 Years Expense Example, with Redemption, 5 Years Expense Example, with Redemption, 10 Years Expense Example, No Redemption, By Year, Column [Text] Expense Example, No Redemption, 1 Year Expense Example, No Redemption, 3 Years Expense Example, No Redemption, 5 Years Expense Example, No Redemption, 10 Years Annual Return Caption [Text] Annual Return, Column [Text] Annual Return, Inception Date Annual Return 1990 Annual Return 1991 Annual Return 1992 Annual Return 1993 Annual Return 1994 Annual Return 1995 Annual Return 1996 Annual Return 1997 Annual Return 1998 Annual Return 1999 Annual Return 2000 Annual Return 2001 Annual Return 2002 Annual Return 2003 Annual Return 2004 Annual Return 2005 Annual Return 2006 Annual Return 2007 Annual Return 2008 Annual Return 2009 Annual Return 2010 Annual Return 2011 Annual Return 2012 Annual Return 2013 Annual Return 2014 Annual Return 2015 Annual Return 2016 Annual Return 2017 Annual Return 2018 Annual Return 2019 Annual Return 2020 Label 1 Year 5 Years 10 Years Since Inception Inception Date Risk/Return Detail [Table] Document Type Document Period End Date Registrant Name Central Index Key Amendment Flag Amendment Description Trading Symbol Document Creation Date Document Effective Date Prospectus Date Fee Waiver or Reimbursement over Assets, Date of Termination Portfolio Turnover, Rate Expense Breakpoint Discounts [Text] Expense Breakpoint, Minimum Investment Required [Amount] Expense Exchange Traded Fund Commissions [Text] Expenses Represent Both Master and Feeder [Text] Expenses Explanation of Nonrecurring Account Fee [Text] Other Expenses, New Fund, Based on Estimates [Text] Acquired Fund Fees and Expenses, Based on Estimates [Text] Expenses Other Expenses Had Extraordinary Expenses Been Included [Text] Expenses Restated to Reflect Current [Text] Expenses Not Correlated to Ratio Due to Acquired Fund Fees [Text] Strategy Portfolio Concentration [Text] Risk Lose Money [Text] Risk Nondiversified Status [Text] Risk Money Market Fund [Text] Risk Not Insured Depository Institution [Text] Risk Caption Risk Column [Text] Risk [Text] Performance Information Illustrates Variability of Returns [Text] Performance One Year or Less [Text] Performance Additional Market Index [Text] Performance Availability Phone [Text] Performance Availability Website Address [Text] Performance Past Does Not Indicate Future [Text] Bar Chart Does Not Reflect Sales Loads [Text] Bar Chart, Reason Selected Class Different from Immediately Preceding Period [Text] Bar Chart, Returns for Class Not Offered in Prospectus [Text] Year to Date Return, Label Bar Chart, Year to Date Return, Date Bar Chart, Year to Date Return Highest Quarterly Return, Label Highest Quarterly Return, Date Highest Quarterly Return Lowest Quarterly Return, Label Lowest Quarterly Return, Date Lowest Quarterly Return Performance Table Does Reflect Sales Loads Performance Table Market Index Changed Index No Deduction for Fees, Expenses, Taxes [Text] Performance Table Uses Highest Federal Rate Performance Table Not Relevant to Tax Deferred Performance Table One Class of after Tax Shown [Text] Performance Table Explanation after Tax Higher Performance Table Footnotes, Reason Performance Information for Class Different from Immediately Preceding Period [Text] Caption Column Money Market Seven Day Yield, Caption [Text] Money Market Seven Day Yield Column [Text] Money Market Seven Day Yield Phone Money Market Seven Day Yield Money Market Seven Day Tax Equivalent Yield Thirty Day Yield Caption Thirty Day Yield Column [Text] Thirty Day Yield Phone Thirty Day Yield Thirty Day Tax Equivalent Yield Putnam Global Health Care fund Class A Class B Class C Class M Class R Class Y MSCI World Health Care Index EX-101.PRE 6 phstx-20151223_pre.xml XBRL PRESENTATION FILE GRAPHIC 8 BarChart1.png IDEA: XBRL DOCUMENT begin 644 BarChart1.png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
(P>/1I[]^[%YY]_CL6+%P- (((D0,RV'_S@!Y@YO?NG4S5;1&Q M;?;LV2@O+\?X\>-Q\N1)//300SAUZE3*OX,SIE\T&D5M;2WR\_,1B43:Y5FV M;!G&CAV+XN)BU-;68M:L63A\^' RU!5&Q*X__>E/F#!A GKV[)D,%1TC8EM6 M5A;6KET+ -BS9P^>?/+)0 1+(K;=N'$#%145R,K*PLB1([%PX<) ?.D2L0T M_O*7O^#TZ=,I[SNTB-JV9\\>W'7778E6+R$$)V1/<6;,F $ .'#@ +[UK6_% MT^^__W[\\I>_! !45E8B&HVBO+P) M5=(A(K;=>>>=N'CQ(@#@TJ5+&#Y\>"!NP"*VG3QY$H,�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htm IDEA: XBRL DOCUMENT v3.6.0.2
Putnam Global Health Care Fund
Fund summary
Goal
Putnam Global Health Care Fund seeks capital appreciation.
Fees and expenses
The following table describes the fees and expenses you may pay if you buy and hold shares of the fund. You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $50,000 in Putnam funds. More information about these and other discounts is available from your financial advisor and in How do I buy fund shares? beginning on page 53 of the fund’s prospectus and in How to buy shares beginning on page II-1 of the fund’s statement of additional information (SAI).
Shareholder fees (fees paid directly from your investment)
Shareholder Fees - Putnam Global Health Care Fund
Class A
Class B
Class C
Class M
Class R
Class Y
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) 5.75% none none 3.50% none none
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) 1.00% [1] 5.00% [2] 1.00% [3] none none none
[1] Applies only to certain redemptions of shares bought with no initial sales charge.
[2] This charge is phased out over six years.
[3] This charge is eliminated after one year.
Annual fund operating expenses (expenses you pay each year as a percentage of the value of your investment)
Annual Fund Operating Expenses - Putnam Global Health Care Fund
Class A
Class B
Class C
Class M
Class R
Class Y
Management fees 0.62% 0.62% 0.62% 0.62% 0.62% 0.62%
Distribution and service (12b-1) fees 0.25% 1.00% 1.00% 0.75% 0.50% none
Other expenses [1] 0.22% 0.22% 0.22% 0.22% 0.22% 0.22%
Total annual fund operating expenses 1.09% 1.84% 1.84% 1.59% 1.34% 0.84%
[1] Restated to reflect current fees resulting from a change to the fund's investor servicing arrangements effective September 1, 2016.
Example
The following hypothetical example is intended to help you compare the cost of investing in the fund with the cost of investing in other funds. It assumes that you invest $10,000 in the fund for the time periods indicated and then, except as indicated, redeem all your shares at the end of those periods. It assumes a 5% return on your investment each year and that the fund’s operating expenses remain the same. Your actual costs may be higher or lower.
Expense Example - Putnam Global Health Care Fund - USD ($)
Expense Example, with Redemption, 1 Year
Expense Example, with Redemption, 3 Years
Expense Example, with Redemption, 5 Years
Expense Example, with Redemption, 10 Years
Class A 680 902 1,141 1,827
Class B 687 879 1,195 1,962
Class C 287 579 995 2,159
Class M 506 834 1,185 2,173
Class R 136 425 734 1,613
Class Y 86 268 466 1,037
Expense Example, No Redemption - Putnam Global Health Care Fund - USD ($)
Expense Example, No Redemption, 1 Year
Expense Example, No Redemption, 3 Years
Expense Example, No Redemption, 5 Years
Expense Example, No Redemption, 10 Years
Class B 187 579 995 1,962
Class C 187 579 995 2,159
Portfolio turnover
The fund pays transaction-related costs, such as commissions, when it buys and sells securities (or “turns over” its portfolio). A higher turnover rate may indicate higher transaction costs and may result in higher taxes when the fund’s shares are held in a taxable account. These costs, which are not reflected in annual fund operating expenses or the above example, affect fund performance. The fund’s turnover rate in the most recent fiscal year was 16%.
Investments
For this non-diversified fund concentrating in the health care industries, we invest mainly in common stocks (growth or value stocks or both) of large and midsize companies worldwide that we believe have favorable investment potential. Under normal circumstances, we invest at least 80% of the fund’s net assets in securities of companies in the health care industries. This policy may be changed only after 60 days’ notice to shareholders. Potential investments include companies that manufacture health care supplies or provide health care-related services, and companies in the research, development, production and marketing of pharmaceuticals and biotechnology products. We may purchase stocks of companies with stock prices that reflect a value lower than that which we place on the company. We may also consider other factors that we believe will cause the stock price to rise. We may consider, among other factors, a company’s valuation, financial strength, growth potential, competitive position in its industry, projected future earnings, cash flows and dividends when deciding whether to buy or sell investments. We may also use derivatives, such as futures, options, certain foreign currency transactions, warrants and swap contracts, for both hedging and non-hedging purposes, and may engage in short sales of securities.
Risks
It is important to understand that you can lose money by investing in the fund.

The value of stocks in the fund’s portfolio may fall or fail to rise over extended periods of time for a variety of reasons, including general financial market conditions, changing market perceptions, changes in government intervention in financial markets, and factors related to a specific issuer or industry. These and other factors may also lead to increased volatility and reduced liquidity in the fund’s portfolio holdings. Growth stocks may be more susceptible to earnings disappointments, and value stocks may fail to rebound. These risks are generally greater for small and midsize companies. The health care industries may be affected by technological obsolescence, changes in regulatory approval policies for drugs, medical devices or procedures and changes in governmental and private payment systems. Our policy of concentrating on a limited group of industries and the fund’s “non-diversified” status, which means the fund may invest a greater percentage of its assets in fewer issuers than a “diversified fund,” can increase the fund’s vulnerability to adverse developments affecting a single industry or issuer, which may result in greater losses and volatility for the fund. The value of international investments traded in foreign currencies may be adversely impacted by fluctuations in exchange rates. International investments, particularly investments in emerging markets, may carry risks associated with potentially less stable economies or governments (such as the risk of seizure by a foreign government, the imposition of currency or other restrictions, or high levels of inflation or deflation), and may be or become illiquid. Our use of derivatives may increase the risks of investing in the fund by increasing investment exposure (which may be considered leverage) or, in the case of many over-the-counter instruments, because of the potential inability to terminate or sell derivatives positions and the potential failure of the other party to the instrument to meet its obligations. Our use of short selling may result in losses if the securities appreciate in value.

The fund may not achieve its goal, and it is not intended to be a complete investment program. An investment in the fund is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.
Performance
The performance information below gives some indication of the risks associated with an investment in the fund by showing the fund’s performance year to year and over time. The bar chart does not reflect the impact of sales charges. If it did, performance would be lower. Please remember that past performance is not necessarily an indication of future results. Monthly performance figures for the fund are available at putnam.com.
Annual total returns for class A shares before sales charges
Bar Chart
Year-to-date performance
through 9/30/16    -6.28%

Best calendar quarter
Q1 2013   13.14%

Worst calendar quarter
Q3 2011     -17.98%
Average annual total returns after sales charges (for periods ending 12/31/15)
Average Annual Total Returns - Putnam Global Health Care Fund
1 Year
5 Years
10 Years
Class A 1.35% 17.10% 9.09%
Class A | after taxes on distributions (1.51%) 14.51% 7.23%
Class A | after taxes on distributions and sale of fund shares 2.98% 13.35% 7.04%
Class B 2.23% 17.40% 9.08%
Class C 5.82% 17.61% 8.91%
Class M 3.25% 17.07% 8.80%
Class R 7.28% 18.20% 9.46%
Class Y 7.81% 18.79% 10.01%
MSCI World Health Care Index (ND) (no deduction for fees, expenses or taxes, other than withholding taxes on reinvested dividends) 6.60% 17.15% 9.25%
After-tax returns reflect the historical highest individual federal marginal income tax rates and do not reflect state and local taxes.
Actual after-tax returns depend on an investor’s tax situation and may differ from those shown. After-tax returns are shown for class A shares only and will vary for other classes. These after-tax returns do not apply if you hold your fund shares through a 401(k) plan, an IRA, or another tax-advantaged arrangement.

Class B share performance reflects conversion to class A shares after eight years.
XML 10 R8.htm IDEA: XBRL DOCUMENT v3.6.0.2
Label Element Value
Risk Return Abstract rr_RiskReturnAbstract  
Document Type dei_DocumentType 485BPOS
Document Period End Date dei_DocumentPeriodEndDate Dec. 31, 2015
Registrant Name dei_EntityRegistrantName PUTNAM GLOBAL HEALTH CARE FUND
Central Index Key dei_EntityCentralIndexKey 0000357295
Amendment Flag dei_AmendmentFlag false
Trading Symbol dei_TradingSymbol PHSTX
Document Creation Date dei_DocumentCreationDate Dec. 30, 2016
Document Effective Date dei_DocumentEffectiveDate Dec. 30, 2016
Prospectus Date rr_ProspectusDate Dec. 30, 2016
Putnam Global Health Care Fund  
Risk Return Abstract rr_RiskReturnAbstract  
Risk/Return [Heading] rr_RiskReturnHeading Fund summary
Objective [Heading] rr_ObjectiveHeading Goal
Objective, Primary [Text Block] rr_ObjectivePrimaryTextBlock Putnam Global Health Care Fund seeks capital appreciation.
Expense [Heading] rr_ExpenseHeading Fees and expenses
Expense Narrative [Text Block] rr_ExpenseNarrativeTextBlock The following table describes the fees and expenses you may pay if you buy and hold shares of the fund. You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $50,000 in Putnam funds. More information about these and other discounts is available from your financial advisor and in How do I buy fund shares? beginning on page 53 of the fund’s prospectus and in How to buy shares beginning on page II-1 of the fund’s statement of additional information (SAI).
Shareholder Fees Caption [Text] rr_ShareholderFeesCaption Shareholder fees (fees paid directly from your investment)
Operating Expenses Caption [Text] rr_OperatingExpensesCaption Annual fund operating expenses (expenses you pay each year as a percentage of the value of your investment)
Portfolio Turnover [Heading] rr_PortfolioTurnoverHeading Portfolio turnover
Portfolio Turnover [Text Block] rr_PortfolioTurnoverTextBlock The fund pays transaction-related costs, such as commissions, when it buys and sells securities (or “turns over” its portfolio). A higher turnover rate may indicate higher transaction costs and may result in higher taxes when the fund’s shares are held in a taxable account. These costs, which are not reflected in annual fund operating expenses or the above example, affect fund performance. The fund’s turnover rate in the most recent fiscal year was 16%.
Portfolio Turnover, Rate rr_PortfolioTurnoverRate 16.00%
Expense Breakpoint Discounts [Text] rr_ExpenseBreakpointDiscounts You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $50,000 in Putnam funds. More information about these and other discounts is available from your financial advisor and in How do I buy fund shares? beginning on page 53 of the fund’s prospectus and in How to buy shares beginning on page II-1 of the fund’s statement of additional information (SAI).
Expense Breakpoint, Minimum Investment Required [Amount] rr_ExpenseBreakpointMinimumInvestmentRequiredAmount $ 50,000
Expense Example [Heading] rr_ExpenseExampleHeading Example
Expense Example Narrative [Text Block] rr_ExpenseExampleNarrativeTextBlock The following hypothetical example is intended to help you compare the cost of investing in the fund with the cost of investing in other funds. It assumes that you invest $10,000 in the fund for the time periods indicated and then, except as indicated, redeem all your shares at the end of those periods. It assumes a 5% return on your investment each year and that the fund’s operating expenses remain the same. Your actual costs may be higher or lower.
Strategy [Heading] rr_StrategyHeading Investments
Strategy Narrative [Text Block] rr_StrategyNarrativeTextBlock For this non-diversified fund concentrating in the health care industries, we invest mainly in common stocks (growth or value stocks or both) of large and midsize companies worldwide that we believe have favorable investment potential. Under normal circumstances, we invest at least 80% of the fund’s net assets in securities of companies in the health care industries. This policy may be changed only after 60 days’ notice to shareholders. Potential investments include companies that manufacture health care supplies or provide health care-related services, and companies in the research, development, production and marketing of pharmaceuticals and biotechnology products. We may purchase stocks of companies with stock prices that reflect a value lower than that which we place on the company. We may also consider other factors that we believe will cause the stock price to rise. We may consider, among other factors, a company’s valuation, financial strength, growth potential, competitive position in its industry, projected future earnings, cash flows and dividends when deciding whether to buy or sell investments. We may also use derivatives, such as futures, options, certain foreign currency transactions, warrants and swap contracts, for both hedging and non-hedging purposes, and may engage in short sales of securities.
Strategy Portfolio Concentration [Text] rr_StrategyPortfolioConcentration For this non-diversified fund concentrating in the health care industries, we invest mainly in common stocks (growth or value stocks or both) of large and midsize companies worldwide that we believe have favorable investment potential.
Risk [Heading] rr_RiskHeading Risks
Risk Narrative [Text Block] rr_RiskNarrativeTextBlock It is important to understand that you can lose money by investing in the fund.

The value of stocks in the fund’s portfolio may fall or fail to rise over extended periods of time for a variety of reasons, including general financial market conditions, changing market perceptions, changes in government intervention in financial markets, and factors related to a specific issuer or industry. These and other factors may also lead to increased volatility and reduced liquidity in the fund’s portfolio holdings. Growth stocks may be more susceptible to earnings disappointments, and value stocks may fail to rebound. These risks are generally greater for small and midsize companies. The health care industries may be affected by technological obsolescence, changes in regulatory approval policies for drugs, medical devices or procedures and changes in governmental and private payment systems. Our policy of concentrating on a limited group of industries and the fund’s “non-diversified” status, which means the fund may invest a greater percentage of its assets in fewer issuers than a “diversified fund,” can increase the fund’s vulnerability to adverse developments affecting a single industry or issuer, which may result in greater losses and volatility for the fund. The value of international investments traded in foreign currencies may be adversely impacted by fluctuations in exchange rates. International investments, particularly investments in emerging markets, may carry risks associated with potentially less stable economies or governments (such as the risk of seizure by a foreign government, the imposition of currency or other restrictions, or high levels of inflation or deflation), and may be or become illiquid. Our use of derivatives may increase the risks of investing in the fund by increasing investment exposure (which may be considered leverage) or, in the case of many over-the-counter instruments, because of the potential inability to terminate or sell derivatives positions and the potential failure of the other party to the instrument to meet its obligations. Our use of short selling may result in losses if the securities appreciate in value.

The fund may not achieve its goal, and it is not intended to be a complete investment program. An investment in the fund is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.
Risk Lose Money [Text] rr_RiskLoseMoney It is important to understand that you can lose money by investing in the fund.
Risk Nondiversified Status [Text] rr_RiskNondiversifiedStatus Our policy of concentrating on a limited group of industries and the fund's "non-diversified" status, which means the fund may invest a greater percentage of its assets in fewer issuers than a "diversified fund," can increase the fund's vulnerability to adverse developments affecting a single industry or issuer, which may result in greater losses and volatility for the fund.
Risk Not Insured Depository Institution [Text] rr_RiskNotInsuredDepositoryInstitution An investment in the fund is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.
Bar Chart and Performance Table [Heading] rr_BarChartAndPerformanceTableHeading Performance
Performance Narrative [Text Block] rr_PerformanceNarrativeTextBlock The performance information below gives some indication of the risks associated with an investment in the fund by showing the fund’s performance year to year and over time. The bar chart does not reflect the impact of sales charges. If it did, performance would be lower. Please remember that past performance is not necessarily an indication of future results. Monthly performance figures for the fund are available at putnam.com.
Performance Information Illustrates Variability of Returns [Text] rr_PerformanceInformationIllustratesVariabilityOfReturns The performance information below gives some indication of the risks associated with an investment in the fund by showing the fund’s performance year to year and over time.
Performance Availability Website Address [Text] rr_PerformanceAvailabilityWebSiteAddress putnam.com
Performance Past Does Not Indicate Future [Text] rr_PerformancePastDoesNotIndicateFuture Please remember that past performance is not necessarily an indication of future results.
Bar Chart [Heading] rr_BarChartHeading Annual total returns for class A shares before sales charges
Bar Chart Does Not Reflect Sales Loads [Text] rr_BarChartDoesNotReflectSalesLoads The bar chart does not reflect the impact of sales charges. If it did, performance would be lower.
Bar Chart Closing [Text Block] rr_BarChartClosingTextBlock Year-to-date performance
through 9/30/16    -6.28%

Best calendar quarter
Q1 2013   13.14%

Worst calendar quarter
Q3 2011     -17.98%
Year to Date Return, Label rr_YearToDateReturnLabel Year-to-date performance through
Bar Chart, Year to Date Return, Date rr_BarChartYearToDateReturnDate Sep. 30, 2016
Bar Chart, Year to Date Return rr_BarChartYearToDateReturn (6.28%)
Highest Quarterly Return, Label rr_HighestQuarterlyReturnLabel Best calendar quarter
Highest Quarterly Return, Date rr_BarChartHighestQuarterlyReturnDate Mar. 31, 2013
Highest Quarterly Return rr_BarChartHighestQuarterlyReturn 13.14%
Lowest Quarterly Return, Label rr_LowestQuarterlyReturnLabel Worst calendar quarter
Lowest Quarterly Return, Date rr_BarChartLowestQuarterlyReturnDate Sep. 30, 2011
Lowest Quarterly Return rr_BarChartLowestQuarterlyReturn (17.98%)
Performance Table Heading rr_PerformanceTableHeading Average annual total returns after sales charges (for periods ending 12/31/15)
Performance Table Uses Highest Federal Rate rr_PerformanceTableUsesHighestFederalRate After-tax returns reflect the historical highest individual federal marginal income tax rates and do not reflect state and local taxes.
Performance Table Not Relevant to Tax Deferred rr_PerformanceTableNotRelevantToTaxDeferred Actual after-tax returns depend on an investor’s tax situation and may differ from those shown.
Performance Table One Class of after Tax Shown [Text] rr_PerformanceTableOneClassOfAfterTaxShown After-tax returns are shown for class A shares only and will vary for other classes.
Performance Table Closing [Text Block] rr_PerformanceTableClosingTextBlock After-tax returns reflect the historical highest individual federal marginal income tax rates and do not reflect state and local taxes.
Actual after-tax returns depend on an investor’s tax situation and may differ from those shown. After-tax returns are shown for class A shares only and will vary for other classes. These after-tax returns do not apply if you hold your fund shares through a 401(k) plan, an IRA, or another tax-advantaged arrangement.

Class B share performance reflects conversion to class A shares after eight years.
Putnam Global Health Care Fund | Class A  
Risk Return Abstract rr_RiskReturnAbstract  
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice 5.75%
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) rr_MaximumDeferredSalesChargeOverOther 1.00% [1]
Management fees rr_ManagementFeesOverAssets 0.62%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets 0.25%
Other expenses rr_OtherExpensesOverAssets 0.22% [2]
Total annual fund operating expenses rr_ExpensesOverAssets 1.09%
Expense Example, with Redemption, 1 Year rr_ExpenseExampleYear01 $ 680
Expense Example, with Redemption, 3 Years rr_ExpenseExampleYear03 902
Expense Example, with Redemption, 5 Years rr_ExpenseExampleYear05 1,141
Expense Example, with Redemption, 10 Years rr_ExpenseExampleYear10 $ 1,827
Annual Return 2006 rr_AnnualReturn2006 2.98%
Annual Return 2007 rr_AnnualReturn2007 (0.63%)
Annual Return 2008 rr_AnnualReturn2008 (17.12%)
Annual Return 2009 rr_AnnualReturn2009 25.17%
Annual Return 2010 rr_AnnualReturn2010 2.06%
Annual Return 2011 rr_AnnualReturn2011 (1.41%)
Annual Return 2012 rr_AnnualReturn2012 21.98%
Annual Return 2013 rr_AnnualReturn2013 41.72%
Annual Return 2014 rr_AnnualReturn2014 27.47%
Annual Return 2015 rr_AnnualReturn2015 7.54%
1 Year rr_AverageAnnualReturnYear01 1.35%
5 Years rr_AverageAnnualReturnYear05 17.10%
10 Years rr_AverageAnnualReturnYear10 9.09%
Putnam Global Health Care Fund | Class B  
Risk Return Abstract rr_RiskReturnAbstract  
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) rr_MaximumDeferredSalesChargeOverOther 5.00% [3]
Management fees rr_ManagementFeesOverAssets 0.62%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets 1.00%
Other expenses rr_OtherExpensesOverAssets 0.22% [2]
Total annual fund operating expenses rr_ExpensesOverAssets 1.84%
Expense Example, with Redemption, 1 Year rr_ExpenseExampleYear01 $ 687
Expense Example, with Redemption, 3 Years rr_ExpenseExampleYear03 879
Expense Example, with Redemption, 5 Years rr_ExpenseExampleYear05 1,195
Expense Example, with Redemption, 10 Years rr_ExpenseExampleYear10 1,962
Expense Example, No Redemption, 1 Year rr_ExpenseExampleNoRedemptionYear01 187
Expense Example, No Redemption, 3 Years rr_ExpenseExampleNoRedemptionYear03 579
Expense Example, No Redemption, 5 Years rr_ExpenseExampleNoRedemptionYear05 995
Expense Example, No Redemption, 10 Years rr_ExpenseExampleNoRedemptionYear10 $ 1,962
1 Year rr_AverageAnnualReturnYear01 2.23%
5 Years rr_AverageAnnualReturnYear05 17.40%
10 Years rr_AverageAnnualReturnYear10 9.08%
Putnam Global Health Care Fund | Class C  
Risk Return Abstract rr_RiskReturnAbstract  
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) rr_MaximumDeferredSalesChargeOverOther 1.00% [4]
Management fees rr_ManagementFeesOverAssets 0.62%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets 1.00%
Other expenses rr_OtherExpensesOverAssets 0.22% [2]
Total annual fund operating expenses rr_ExpensesOverAssets 1.84%
Expense Example, with Redemption, 1 Year rr_ExpenseExampleYear01 $ 287
Expense Example, with Redemption, 3 Years rr_ExpenseExampleYear03 579
Expense Example, with Redemption, 5 Years rr_ExpenseExampleYear05 995
Expense Example, with Redemption, 10 Years rr_ExpenseExampleYear10 2,159
Expense Example, No Redemption, 1 Year rr_ExpenseExampleNoRedemptionYear01 187
Expense Example, No Redemption, 3 Years rr_ExpenseExampleNoRedemptionYear03 579
Expense Example, No Redemption, 5 Years rr_ExpenseExampleNoRedemptionYear05 995
Expense Example, No Redemption, 10 Years rr_ExpenseExampleNoRedemptionYear10 $ 2,159
1 Year rr_AverageAnnualReturnYear01 5.82%
5 Years rr_AverageAnnualReturnYear05 17.61%
10 Years rr_AverageAnnualReturnYear10 8.91%
Putnam Global Health Care Fund | Class M  
Risk Return Abstract rr_RiskReturnAbstract  
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice 3.50%
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) rr_MaximumDeferredSalesChargeOverOther none
Management fees rr_ManagementFeesOverAssets 0.62%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets 0.75%
Other expenses rr_OtherExpensesOverAssets 0.22% [2]
Total annual fund operating expenses rr_ExpensesOverAssets 1.59%
Expense Example, with Redemption, 1 Year rr_ExpenseExampleYear01 $ 506
Expense Example, with Redemption, 3 Years rr_ExpenseExampleYear03 834
Expense Example, with Redemption, 5 Years rr_ExpenseExampleYear05 1,185
Expense Example, with Redemption, 10 Years rr_ExpenseExampleYear10 $ 2,173
1 Year rr_AverageAnnualReturnYear01 3.25%
5 Years rr_AverageAnnualReturnYear05 17.07%
10 Years rr_AverageAnnualReturnYear10 8.80%
Putnam Global Health Care Fund | Class R  
Risk Return Abstract rr_RiskReturnAbstract  
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) rr_MaximumDeferredSalesChargeOverOther none
Management fees rr_ManagementFeesOverAssets 0.62%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets 0.50%
Other expenses rr_OtherExpensesOverAssets 0.22% [2]
Total annual fund operating expenses rr_ExpensesOverAssets 1.34%
Expense Example, with Redemption, 1 Year rr_ExpenseExampleYear01 $ 136
Expense Example, with Redemption, 3 Years rr_ExpenseExampleYear03 425
Expense Example, with Redemption, 5 Years rr_ExpenseExampleYear05 734
Expense Example, with Redemption, 10 Years rr_ExpenseExampleYear10 $ 1,613
1 Year rr_AverageAnnualReturnYear01 7.28%
5 Years rr_AverageAnnualReturnYear05 18.20%
10 Years rr_AverageAnnualReturnYear10 9.46%
Putnam Global Health Care Fund | Class Y  
Risk Return Abstract rr_RiskReturnAbstract  
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) rr_MaximumDeferredSalesChargeOverOther none
Management fees rr_ManagementFeesOverAssets 0.62%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets none
Other expenses rr_OtherExpensesOverAssets 0.22% [2]
Total annual fund operating expenses rr_ExpensesOverAssets 0.84%
Expense Example, with Redemption, 1 Year rr_ExpenseExampleYear01 $ 86
Expense Example, with Redemption, 3 Years rr_ExpenseExampleYear03 268
Expense Example, with Redemption, 5 Years rr_ExpenseExampleYear05 466
Expense Example, with Redemption, 10 Years rr_ExpenseExampleYear10 $ 1,037
1 Year rr_AverageAnnualReturnYear01 7.81%
5 Years rr_AverageAnnualReturnYear05 18.79%
10 Years rr_AverageAnnualReturnYear10 10.01%
Putnam Global Health Care Fund | after taxes on distributions | Class A  
Risk Return Abstract rr_RiskReturnAbstract  
1 Year rr_AverageAnnualReturnYear01 (1.51%)
5 Years rr_AverageAnnualReturnYear05 14.51%
10 Years rr_AverageAnnualReturnYear10 7.23%
Putnam Global Health Care Fund | after taxes on distributions and sale of fund shares | Class A  
Risk Return Abstract rr_RiskReturnAbstract  
1 Year rr_AverageAnnualReturnYear01 2.98%
5 Years rr_AverageAnnualReturnYear05 13.35%
10 Years rr_AverageAnnualReturnYear10 7.04%
Putnam Global Health Care Fund | MSCI World Health Care Index (ND) (no deduction for fees, expenses or taxes, other than withholding taxes on reinvested dividends)  
Risk Return Abstract rr_RiskReturnAbstract  
1 Year rr_AverageAnnualReturnYear01 6.60%
5 Years rr_AverageAnnualReturnYear05 17.15%
10 Years rr_AverageAnnualReturnYear10 9.25%
[1] Applies only to certain redemptions of shares bought with no initial sales charge.
[2] Restated to reflect current fees resulting from a change to the fund's investor servicing arrangements effective September 1, 2016.
[3] This charge is phased out over six years.
[4] This charge is eliminated after one year.
XML 11 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.6.0.2 html 11 86 1 true 10 0 false 2 false true R1.htm 010000 - Document - Risk/Return Summary {Unlabeled} Sheet http://xbrl.sec.gov/rr/role/RiskReturn Risk/Return Summary 1 false false R8.htm 040000 - Disclosure - Risk/Return Detail Data {Elements} Sheet http://xbrl.sec.gov/rr/role/RiskReturnDetailData Risk/Return Detail Data 2 false false All Reports Book All Reports phstx-20151223.xml phstx-20151223.xsd phstx-20151223_def.xml phstx-20151223_lab.xml phstx-20151223_pre.xml BarChart1.png true false ZIP 16 0000928816-17-000036-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000928816-17-000036-xbrl.zip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